Alyeska Investment Group
LKFT

Alyeska Investment Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Alyeska Investment Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,000
Closed -$2.81M – 408
2018
Q3 		$2.81M Buy
+25,000
New +$2.64M 0.03% 279
2015
Q3 		– Sell
-39,320
Closed -$2.02M – 493
2015
Q2 		$2.02M Buy
+39,320
New +$2.09M 0.02% 347

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Alyeska Investment Group's LKFT Position: Q4 2018 in Review

Alyeska Investment Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2018, closing a stake of 25,000 shares — an estimated $2.81M sold.

Alyeska Investment Group first reported a position in LKFT in Q2 2015 and held it in 2 quarters. The position peaked at $2.81M in Q3 2018. 85 funds tracked by Wall St. Rank hold LKFT as of Q4 2018.

  • Alyeska Investment Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 25,000 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2018, an estimated $2.81M.
  • Alyeska Investment Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and held it in 2 quarters.
  • Alyeska Investment Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $2.81M in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2018.

Based on Alyeska Investment Group's 13F filing for Q4 2018, filed 14 Feb 2019.